Celiac disease: is it really possible to overcome duodenal biopsy?

Elisabetta Grande1, Silvia Ferranti, Carla Gaggiano

  • 1University of Siena, Siena, Italy.. grande.elisabetta@yahoo.it.

Insights

This case highlights potential celiac disease diagnosis in a child with high antibodies but no biopsy findings, challenging typical diagnostic relationships.

Area of Science:

  • Pediatric Gastroenterology
  • Immunology
  • Celiac Disease Diagnostics

Background:

  • Celiac disease screening is crucial in children with a family history.
  • Diagnosis typically relies on antibody levels and intestinal biopsy findings.
  • ESPGHAN guidelines offer criteria for diagnosing celiac disease without biopsy in specific high-risk cases.

Observation:

  • A two-year-five-month-old child presented with high celiac disease antibodies (tTG IgA: 100 UI/ml) and a high-risk HLA genotype (DQ2 heterodymer).
  • Despite elevated transaminases and positive EMA IgA, intestinal biopsy showed no mucosal damage (Marsh 0).
  • The child remained asymptomatic on a free diet, with antibody titers normalizing.

Findings:

  • The case presents a discrepancy between high antibody levels and negative histology, challenging the expected correlation.
  • High-risk HLA and elevated antibodies suggested celiac disease, but the Marsh 0 biopsy led to a potential celiac disease diagnosis.
  • This contrasts with literature suggesting a linear relationship between antibody levels and histological damage in potential celiac disease.

Implications:

  • This case questions the strict adherence to diagnostic guidelines when clinical and histological findings diverge.
  • It emphasizes the importance of considering individual patient presentations beyond antibody titers and HLA status.
  • Further research may be needed to refine diagnostic criteria for potential celiac disease, especially in pediatric cases with atypical presentations.

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.0K
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
759
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
467
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
655
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
606
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
910